Agrin gene therapy
Agrin gene therapy has been studied in 1 paper since 2024: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Mar 9, 2024: “Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice”.
1 paper studies it3 findingsUpdated
See all 1 papers on agrin gene therapy
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Natural Science Foundation of China and 1 more
- Animals1
What did studies of agrin gene therapy find?
3Studies of agrin gene therapy measured 3 outcomes: DAG1, hippo–YAP signaling and muscle capacity.
DAG1
upin mice1
1 study
DAG1
upin mice1
Agrin gene therapy increases DAG1 in mice.
“concurrent upregulation of dystroglycan expression”
Animalsskeletal muscle
Cell death & disease
Hippo–YAP signaling
upin mice1
1 study
Hippo–YAP signaling
upin mice1
Agrin gene therapy activates hippo–YAP signaling in mice.
“Agrin-mediated improvement in muscle function occurs through the stimulation of Yap signaling”
Animalsskeletal muscle
Cell death & disease
Muscle capacity
upin mice1
1 study
Muscle capacity
upin mice1
Agrin gene therapy improves muscle capacity in mice (adenovirus-mediated gene transfer).
“elevation of a miniaturized form of Agrin in skeletal muscle through adenovirus-mediated gene transfer induces enhanced muscle capacity in aged mice”
Animalsadenovirus-mediated gene transferminiaturized formskeletal muscle
Cell death & disease